EU drug regulator aims to conclude Merck COVID-19 antiviral pill approval by the end of 2021

Reuters

– The European Medicine Agency’s review to approve Merck’s antiviral pill molnupiravir, developed with Ridgeback Therapeutics, is set to conclude by the end of the year, the regulator’s head of vaccine strategy said on Thursday.

Marco Cavaleri said in a media briefing that a review on the use of Pfizer’s COVID-19 vaccine in five- to 11-year-olds should see a recommendation by the end of this month and possibly as soon as the end of next week.

(Reporting by Pushkala Aripaka and Alistair Smout, editing by Mark Heinrich)

Related News:   Factbox-Seven US Senate races to watch in 2024

tagreuters.com2021binary_LYNXMPEHAH0SR-BASEIMAGE

You appear to be using an ad blocker

Shore News Network is a free website that does not use paywalls or charge for access to original, breaking news content. In order to provide this free service, we rely on advertisements. Please support our journalism by disabling your ad blocker for this website.